Publications

Found 96 results
Type [ Year(Desc)]
2012
Polstein, LR, and Gersbach, CA. "Photoregulated gene expression in human cells with light-inducible engineered transcription factors." ASME 2012 Summer Bioengineering Conference, SBC 2012 (2012): 351-352.
2013
Gersbach, CA. "Engineered Proteins for Controlling Gene Expression." Handbook of Stem Cells 1 (2013): 125-138.
Ousterout, DG, Perez-Pinera, P, Thakore, PI, Kabadi, AM, Brown, MT, Qin, X, Fédrigo, O, Mouly, V, Tremblay, JP, and Gersbach, CA. "Erratum: Reading Frame correction by targeted genome editing restores dystrophin expression in cells from duchenne muscular dystrophy patients (Molecular Therapy (2013) 21 (1718-1726) DOI: 10.1038/mt.2013.111)." Molecular Therapy 21, no. 11 (2013): 2130-.
Duvall, CL, Prokop, A, Gersbach, CA, and Davidson, JM. "Gene Delivery into Cells and Tissues." (2013): 687-723.
Bhakta, MS, Henry, IM, Ousterout, DG, Das, KT, Lockwood, SH, Meckler, JF, Wallen, MC, Zykovich, A, Yu, Y, Leo, H et al. "Highly active zinc-finger nucleases by extended modular assembly." Genome research 23, no. 3 (2013): 530-538.
Dumbauld, DW, Lee, TT, Singh, A, Scrimgeour, J, Gersbach, CA, Zamir, EA, Fu, J, Chen, CS, Curtis, JE, Craig, SW et al. "How vinculin regulates force transmission." Proceedings of the National Academy of Sciences of USA 110, no. 24 (2013): 9788-9793.
Ousterout, DG, Perez-Pinera, P, Thakore, PI, Kabadi, AM, Brown, MT, Qin, X, Fédrigo, O, Mouly, V, Tremblay, JP, and Gersbach, CA. "Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients." Molecular Therapy 21, no. 9 (2013): 1718-1726.
Perez-Pinera, P, Kocak, DD, Vockley, CM, Adler, AF, Kabadi, AM, Polstein, LR, Thakore, PI, Glass, KA, Ousterout, DG, Leong, KW et al. "RNA-guided gene activation by CRISPR-Cas9-based transcription factors." Nature Methods 10, no. 10 (2013): 973-976.
Gibson, TM, and Gersbach, CA. "The role of single-cell analyses in understanding cell lineage commitment." Biotechnology Journal 8, no. 4 (2013): 397-407.
Perez-Pinera, P, Ousterout, DG, Brunger, JM, Farin, AM, Glass, KA, Guilak, F, Crawford, GE, Hartemink, AJ, and Gersbach, CA. "Synergistic and Tunable Gene Activation by Combinations of Synthetic Transcription Factors." In Molecular Therapy, S93. Vol. 21., 2013.
Perez-Pinera, P, Ousterout, DG, Brunger, JM, Farin, AM, Glass, KA, Guilak, F, Crawford, GE, Hartemink, AJ, and Gersbach, CA. "Synergistic and tunable human gene activation by combinations of synthetic transcription factors." Nature Methods 10, no. 3 (2013): 239-242.
Gersbach, CA, and III, CFB. "Targeted plasmid integration into the Human Genome by engineered recombinases." Topics in Current Genetics 23 (2013): 267-284.
Tremblay, JP, Xiao, X, Aartsma-Rus, A, Barbas, C, Blau, HM, Bogdanove, AJ, Boycott, K, Braun, S, Breakefield, XO, Bueren, JA et al. "Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases." Molecular Therapy 21, no. 2 (2013): 266-268.
Glass, KA, Brunger, JM, Gersbach, CA, and Guilak, F. "TUNABLE EXPRESSION OF IL-1RA IN GENETICALLY MODIFIED MESENCHYMAL STEM CELLS FOR CARTILAGE TISSUE ENGINEERING." In Osteoarthritis and Cartilage, S282-S283. Vol. 21., 2013.
Gaj, T, Gersbach, CA, and Barbas, CF. "ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering." Trends in Biotechnology 31, no. 7 (2013): 397-405.
2014
Gersbach, CA, and Perez-Pinera, P. "Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine." Expert Opinion on Therapeutic Targets 18, no. 8 (2014): 835-839.
Gersbach, CA, Gaj, T, and Barbas, CF. "Comparing Genome Editing Technologies." Genetic Engineering and Biotechnology News 34, no. 5 (2014): 1, 32-34.
High, K, Gregory, PD, and Gersbach, C. "CRISPR technology for gene therapy." Nature Medicine 20, no. 5 (2014): 476-477.
Chakraborty, S, Ji, H, Kabadi, AM, Gersbach, CA, Christoforou, N, and Leong, KW. "A CRISPR/Cas9-based system for reprogramming cell lineage specification." Stem Cell Reports 3, no. 6 (2014): 940-947.
Kabadi, AM, and Gersbach, CA. "Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression." Methods 69, no. 2 (2014): 188-197.
Kabadi, AM, and Gersbach, CA. "Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression." Methods 69, no. 2 (2014): 188-197.
Gersbach, CA. "Genome engineering: the next genomic revolution." Nature Methods 11, no. 10 (2014): 1009-1011.
Polstein, LR, and Gersbach, CA. "Light-inducible gene regulation with engineered zinc finger proteins." Methods in molecular biology (Clifton, N.J.) 1148 (2014): 89-107.
Kabadi, AM, Ousterout, DG, Hilton, IB, and Gersbach, CA. "Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector." Nucleic Acids Research 42, no. 19 (2014).
Schulz, E, Bergmann, T, Gebbing, M, Schildgen, V, Schildgen, O, Gersbach, C, and Ehrhardt, A. "Mutation Detection Following Non-Homologous End Joining (NHEJ): A Comparison of Different Semi Quantitative and Quantitative Methods." In Molecular Therapy, S126-S127. Vol. 22., 2014.

Pages